又一款ADC药物获批治疗乳腺癌:阿斯利康、科伦博泰纷纷入局

第一财经
28 Dec 2024

靶向TROP2(人滋养细胞表面抗原2)的抗体偶联药物(ADC)在乳腺癌的治疗方面正在快速取得进展。12月27日,阿斯利康与第一三共联合开发的ADC药物德达博妥单抗(Datroway)在日本获批,用于治疗接受过化疗后的激素受体(HR)阳性、HER2阴性不可切除或复发性乳腺癌成人患者。日本药监机构的批准为德达博妥单抗推向全球市场打开大门。在中国,德达博妥单抗针对上述乳腺癌适应症的上市申请已经于今年3月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10